跳至主要内容
临床试验/NCT02333448
NCT02333448已完成不适用

Diagnostic Value of PCR Genetic Amplification and Mannan Antigenemia Coupled With Antimannan Antibodies in Intensive Care Patients With Suspected Invasive Candidiasis

Centre Hospitalier Universitaire Dijon1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2015年6月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
80
试验地点
1
主要终点
Change from the start of treatment in genomic DNA of Candida sp. by quantitative PCR

研究概览

简要总结

The study consists in taking 4 tubes of blood at different times over a period of 10 days, via a catheter (central venous or arterial catheter) already in place in the usual therapeutic management. These samples will make it possible to measure blood levels of certain markers specific to invasive candidiasis. PCR will be used to quantify fungal load precisely, that is to say the quantity of yeast present in the blood and to monitor this quantity over time.

These samples will be transferred to a specialized unit and stored for a maximum of three years for use at the end of the study.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient informed about the study
  • Patients aged at least 18 years admitted to a medical Intensive Care or general intensive care
  • Patients with suspected invasive candidiasis - that is to say:
  • Presenting persistent sepsis despite broad-spectrum antibiotherapy for at least 48 hours or targeted antibiotherapy for a documented bacterial infection (sepsis will be defined according to:
  • the usual SIRS criteria, at least 2 of the following 4: temperature > 38°C or < 36°C, tachycardia > 90/min, respiratory rate > 20/min or blood pressure carbon dioxide (PaCO2 ) < 32 mmHg, leukocytosis > 12000/mm3 or < 4000/mm3 or > 10% of immature forms.
  • Persistent hemodynamic instability (impossibility to significantly diminish catecholamine requirement, need for rapid vascular resuscitation > 1000 ml over the previous 24 hours)
  • Candida score ≥ 3 with multifocal colonization
  • Decision to initiate echinocandin therapy made by the clinician in charge of the patient

排除标准

  • Treatment with echinocandin > 1 day in the week preceding inclusion
  • Patients not covered by national health insurance
  • Pregnant or breast-feeding women

结局指标

主要结局

Change from the start of treatment in genomic DNA of Candida sp. by quantitative PCR

时间窗: At day 1, day 3, day 5, Day 7 and Day 10 after the start of antifungal treatment with echinocandin.

次要结局

  • Change from the start of treatment in mannan antigenemia and antimannan antibodies(At day 1, day 5 and day 10 after the start of treatment)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验